Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

  • J. K. Overbeek
  • , R. ter Heine
  • , H. M.W. Verheul
  • , E. Chatelut
  • , M. A. Rudek
  • , H. Gurney
  • , R. Plummer
  • , D. C. Gilbert
  • , T. Buclin
  • , D. M. Burger
  • , H. J. Bloemendal
  • , N. P. van Erp*
  • *Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

11 Citations (Scopus)
53 Downloads (Pure)
Original languageEnglish
Article number100749
JournalESMO Open
Volume8
Issue number1
DOIs
Publication statusPublished - Feb 2023

Bibliographical note

Funding Information:
This work was supported by ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program [grant 10140021910005 ]. MAR was supported by NCI grants UM1CA186691 , U24CA247648 , and P30CA006973 .

Cite this